Abstract
Dexfenfluramine chlorhydrate (Isomeride) is a drug used for the treatment of obesity (Finer etal. 1985; Enzi etal. 1986). This compound reduces disorders of eating behavior, with a specific effect on diet selection, carbohydrate-rich meals being decreased while protein consumption is unaffected (Wurtman et al. 1985). Such a shift in diet selection can be produced experimentally by hypothalamic injection of serotonin (5-HT) (Blundell 1984; Leibowitz 1985). Dexfenfluramine is an indirect agonist of 5-HT, increasing its release and inhibiting its reuptake (Garattini etal. 1985). 5-HT terminals are widely distributed in the cerebral cortex, so dexfenfluramine could act on large brain areas. Such a general action can be studied by quantitative EEG (Q-EEG) and its brain mapping. The aim of this study is to describe the EEG variations induced by three different doses of dexfenfluramine in healthy young subjects.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Blundell JE (1984) Serotonin and appetite. Neuropharmacology 23:1537–1551
Enzi G, Crepaldi G et al. (1986) Efficacy and safety of dextrofenfluramine in obese patients: a multicenter study. 15th CLINP Congress, Puerto Rico, 14–17 Dec 1986
Finer N, Craddock D, Lavielle R, Keen H (1985) Dextrofenfluramine in the treatment of refractory obesity. Curr Ther Res 38:847–854
Fink M, Shapiro DM, Itil T (1971) EEG profiles of fenfluramine, amoborbitol nd dextroamphetamine in normal volunteers. Psychopharmacologia 22:369–383
Garattini S, Mennini T, Bendotti C, Invernizzi R, Samanin R (1985) Neurochemical mechanism of action of drugs which modify feedings via the serotoninergic system. Appetite 2 (Suppl): 15–38
Leibowitz SF, Shor-Posner E (1986) Hypothalmic serotonin in control of eating behavior. In: Ferrari F, Brambilla F (eds) Disorders of eating behavior. Pergamon, Oxford, pp 343–352
Rowland NE, Carlton J (1986) Neurobiology of an anorectic drug: fenfluramine. Prog Neu-robiol 27:13–62
Saletu B, Gründerger J (1985) Classification and determination of cerebral bioavailability of fluoxetine: pharmacokinetic, pharmaco-EEG and psychometric analysis. J Clin Psychiatry 46(3): 45–52
Saletu B, Gründerger J, Rajna P., Karobath M (1980) Cloroxamine and fluvoxamine-2 biogenic amine re-uptake inhibiting anti-depressants. Quantitative EEG, psychometric and pharmacokinetic studies in man. J Neural Transm 49:63–86
Saletu B, Gründerger J, Linzmayer L (1986) On central effects of serotonin re-uptake inhibitors: quantitative EEG and psychometric studies with sectroline and zimelidine. J Neural Transm 67:241–266
Wurtman J, Wurtman R, Mark S, Tsay R, Gilbert W, Growden J (1985) D-Fenfluramine selectively suppresses carbohydrate snacking by obese subjects. Int J Eating Disorders 4:89–99
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Sebban, C., Le Roch, K., Benkemoun, G., Debouzy, C., Baud, P. (1989). Dexfenfluramine Profile in Quantitative EEG and Its Topographical Aspects. In: Maurer, K. (eds) Topographic Brain Mapping of EEG and Evoked Potentials. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-72658-3_31
Download citation
DOI: https://doi.org/10.1007/978-3-642-72658-3_31
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-72660-6
Online ISBN: 978-3-642-72658-3
eBook Packages: Springer Book Archive